These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23160248)

  • 1. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 3. Effects of renal and hepatic impairment.
    Preskorn SH
    J Psychiatr Pract; 2012 Nov; 18(6):430-7. PubMed ID: 23160248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 2. Metabolism and elimination.
    Preskorn SH
    J Psychiatr Pract; 2012 Sep; 18(5):361-8. PubMed ID: 22995963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: part 1.
    Preskorn SH
    J Psychiatr Pract; 2012 May; 18(3):199-204. PubMed ID: 22617084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics.
    Spina E; de Leon J
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):721-46. PubMed ID: 24494611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between antiepileptics and second-generation antipsychotics.
    de Leon J; Santoro V; D'Arrigo C; Spina E
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):311-34. PubMed ID: 22332980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia.
    Macaluso M; Kazanchi H; Preskorn SH
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1317-27. PubMed ID: 26173973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and metabolism update for some recent antipsychotics.
    Caccia S
    Expert Opin Drug Metab Toxicol; 2011 Jul; 7(7):829-46. PubMed ID: 21476873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of common antipsychotics.
    Patteet L; Morrens M; Maudens KE; Niemegeers P; Sabbe B; Neels H
    Ther Drug Monit; 2012 Dec; 34(6):629-51. PubMed ID: 23149440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinically relevant drug interactions with new generation antidepressants and antipsychotics].
    Eckert A
    Ther Umsch; 2009 Jun; 66(6):485-92. PubMed ID: 19496045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population.
    Guay DR
    Consult Pharm; 2011 Aug; 26(8):579-82. PubMed ID: 21840821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
    Ereshefsky L; Mascarenas CA
    J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.
    Slim M; Medina-Caliz I; Gonzalez-Jimenez A; Cabello MR; Mayoral-Cleries F; Lucena MI; Andrade RJ
    Drug Saf; 2016 Oct; 39(10):925-43. PubMed ID: 27449495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatic tolerance of atypical antipsychotic drugs].
    Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching in the era of atypical antipsychotics. An updated review.
    Weiden PJ
    Postgrad Med; 2006 Sep; Spec No():27-44. PubMed ID: 17128659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
    Ishiyama T; Tokuda K; Ishibashi T; Ito A; Toma S; Ohno Y
    Eur J Pharmacol; 2007 Oct; 572(2-3):160-70. PubMed ID: 17662268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
    Citrome L
    Clin Schizophr Relat Psychoses; 2011 Jan; 4(4):251-7. PubMed ID: 21177242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.